Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03108131 · ClinicalTrials.gov registry record · Phase 2
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT03108131: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03108131 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03108131, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This phase II trial studies how well cobimetinib and atezolizumab work in treating participants with rare tumors that have spread to other places in the body (advanced) or that does not respond to treatment (refractory). Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cobimetinib and atezolizumab may work better in treating participants with advanced or refractory rare tumors.
Interventions
- DRUG Atezolizumab
- DRUG Cobimetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-04-07 |
| Est. Completion | 2024-04-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03108131
The ClinicalTrials.gov registry entry for NCT03108131 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT03108131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03108131 about?
NCT03108131 is a clinical study titled "Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors". This phase II trial studies how well cobimetinib and atezolizumab work in treating participants with rare tumors that have spread to other places in the body (advanced) or that does not respond to treatment (refractory). Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes ...
What is the current status of trial NCT03108131?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2017-04-07. Estimated completion is 2024-04-02.
What interventions are being tested in trial NCT03108131?
The interventions under investigation include: Atezolizumab (DRUG), Cobimetinib (DRUG).
Who is sponsoring clinical trial NCT03108131?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.